Corey Davis
Stock Analyst at HC Wainwright & Co.
(3.00)
# 1,446
Out of 5,012 analysts
17
Total ratings
75%
Success rate
25.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corey Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Reiterates: Neutral | $480 → $390 | $56.56 | +589.53% | 5 | May 12, 2020 | |
| SCYX SCYNEXIS | Assumes: Buy | $50 | $0.78 | +6,336.66% | 3 | May 7, 2018 | |
| VTVT vTv Therapeutics | Downgrades: Neutral | $560 → $40 | $21.60 | +85.19% | 2 | Apr 10, 2018 | |
| LPCN Lipocine | Initiates: Buy | $170 | $3.16 | +5,279.75% | 1 | Mar 29, 2018 | |
| VNDA Vanda Pharmaceuticals | Initiates: Buy | $20 | $5.46 | +266.30% | 2 | Jan 19, 2018 | |
| PCRX Pacira BioSciences | Initiates: Buy | $50 | $23.41 | +113.58% | 3 | Jan 19, 2018 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Neutral | $144 | $137.78 | +4.51% | 1 | Aug 25, 2017 |
Nektar Therapeutics
May 12, 2020
Reiterates: Neutral
Price Target: $480 → $390
Current: $56.56
Upside: +589.53%
SCYNEXIS
May 7, 2018
Assumes: Buy
Price Target: $50
Current: $0.78
Upside: +6,336.66%
vTv Therapeutics
Apr 10, 2018
Downgrades: Neutral
Price Target: $560 → $40
Current: $21.60
Upside: +85.19%
Lipocine
Mar 29, 2018
Initiates: Buy
Price Target: $170
Current: $3.16
Upside: +5,279.75%
Vanda Pharmaceuticals
Jan 19, 2018
Initiates: Buy
Price Target: $20
Current: $5.46
Upside: +266.30%
Pacira BioSciences
Jan 19, 2018
Initiates: Buy
Price Target: $50
Current: $23.41
Upside: +113.58%
Jazz Pharmaceuticals
Aug 25, 2017
Initiates: Neutral
Price Target: $144
Current: $137.78
Upside: +4.51%